Bionano Genomics Overview
- Year Founded
-
2003

- Status
-
Public
- Employees
-
344

- Stock Symbol
-
BNGO

- Investments
-
3
- Share Price
-
$5.40
- (As of Tuesday Closing)
Bionano Genomics General Information
Description
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Contact Information
Website
www.bionano.comCorporate Office
- 9540 Towne Centre Drive
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 9540 Towne Centre Drive
- Suite 100
- San Diego, CA 92121
- United States
Bionano Genomics Timeline
Bionano Genomics Stock Performance
As of 11-Feb-2025, Bionano Genomics’s stock price is $5.40. Its current market cap is $12.6M with 2.33M shares.
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$5.40 | $5.22 | $4.75 - $81.00 | $12.6M | 2.33M | 199K | -$138.00 |
Bionano Genomics Financials Summary
As of 30-Sep-2024, Bionano Genomics has a trailing 12-month revenue of $33.3M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 47,663 | 19,968 | 263,712 | 538,591 |
Revenue | 33,334 | 36,116 | 27,802 | 17,981 |
EBITDA | (118,268) | (216,711) | (122,081) | (74,091) |
Net Income | (135,783) | (232,493) | (132,596) | (72,435) |
Total Assets | 87,362 | 214,404 | 307,502 | 377,100 |
Total Debt | 22,453 | 79,413 | 11,668 | 10,696 |
Bionano Genomics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Bionano Genomics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Bionano Genomics Comparisons
Industry
Financing
Details
Bionano Genomics Competitors (38)
One of Bionano Genomics’s 38 competitors is Akoya Biosciences, a Formerly VC-backed company based in Marlborough, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Akoya Biosciences | Formerly VC-backed | Marlborough, MA | ||||
Cytek | Formerly VC-backed | Fremont, CA | ||||
10x Genomics | Private Equity-Backed | Pleasanton, CA | ||||
Singular Genomics | Formerly VC-backed | San Diego, CA | ||||
Pacific Biosciences | Formerly VC-backed | Menlo Park, CA |
Bionano Genomics Patents
Bionano Genomics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240167957-A1 | Top hat illumination biological sample imaging devices, and methods of using the same | Pending | 23-Nov-2022 | ||
US-20210230664-A1 | Labeling of dna | Pending | 25-Jun-2018 | ||
EP-4159872-A1 | Labeling of dna | Active | 25-Jun-2018 | ||
CA-3104649-A1 | Labeling of dna | Pending | 25-Jun-2018 | ||
EP-3810801-A1 | Labeling of dna | Active | 25-Jun-2018 | C12Q1/6841 |
Bionano Genomics Signals
Bionano Genomics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Bionano Genomics Acquisitions (3)
Bionano Genomics’s most recent deal was a Merger/Acquisition with Purigen Biosystems for . The deal was made on 30-Nov-2022.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Purigen Biosystems | 30-Nov-2022 | Merger/Acquisition | Biotechnology | ||
BioDiscovery | 12-Oct-2021 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
Lineagen | 21-Aug-2020 | Merger/Acquisition | Other Healthcare Technology Systems |
Bionano Genomics ESG
Risk Overview
Risk Rating
Updated April, 28, 2023
29.35 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile

Pharmaceuticals
Industry
of 898
Rank
Percentile

Biotechnology
Subindustry
of 402
Rank
Percentile

Bionano Genomics FAQs
-
When was Bionano Genomics founded?
Bionano Genomics was founded in 2003.
-
Where is Bionano Genomics headquartered?
Bionano Genomics is headquartered in San Diego, CA.
-
What is the size of Bionano Genomics?
Bionano Genomics has 344 total employees.
-
What industry is Bionano Genomics in?
Bionano Genomics’s primary industry is Other Healthcare Technology Systems.
-
Is Bionano Genomics a private or public company?
Bionano Genomics is a Public company.
-
What is Bionano Genomics’s stock symbol?
The ticker symbol for Bionano Genomics is BNGO.
-
What is the current stock price of Bionano Genomics?
As of 11-Feb-2025 the stock price of Bionano Genomics is $5.40.
-
What is the current market cap of Bionano Genomics?
The current market capitalization of Bionano Genomics is $12.6M.
-
What is Bionano Genomics’s current revenue?
The trailing twelve month revenue for Bionano Genomics is $33.3M.
-
Who are Bionano Genomics’s competitors?
Akoya Biosciences, Cytek, 10x Genomics, Singular Genomics, and Pacific Biosciences are some of the 38 competitors of Bionano Genomics.
-
What is Bionano Genomics’s annual earnings per share (EPS)?
Bionano Genomics’s EPS for 12 months was -$138.00.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »